Oral phosphodiesterase 4B inhibitor shows promise for preventing lung function decline in IPF

SAN FRANCISCO — Treatment with an oral preferential phosphodiesterase 4B inhibitor prevented lung function decline among patients with idiopathic pulmonary fibrosis, regardless of background antifibrotic therapy use.
The phase 2 trial enrolled 147 adults with IPF who were randomly assigned to an oral preferential inhibitor of the phosphodiesterase 4B (PDE4B) subtype (BI 1015550, Boehringer Ingelheim) at a dose of 18 mg or placebo twice daily. Treatment continued for 12 weeks, followed by a 1-week follow-up period.
Treatment with the PDE4B inhibitor appeared to stabilize lung function

SAN FRANCISCO — Treatment with an oral preferential phosphodiesterase 4B inhibitor prevented lung function decline among patients with idiopathic pulmonary fibrosis, regardless of background antifibrotic therapy use.
The phase 2 trial enrolled 147 adults with IPF who were randomly assigned to an oral preferential inhibitor of the phosphodiesterase 4B (PDE4B) subtype (BI 1015550, Boehringer Ingelheim) at a dose of 18 mg or placebo twice daily. Treatment continued for 12 weeks, followed by a 1-week follow-up period.
Treatment with the PDE4B inhibitor appeared to stabilize lung function